Abourehab Mohammed A S, Khames Ahmed, Genedy Samar, Mostafa Shahin, Khaleel Mohammad A, Omar Mahmoud M, El Sisi Amani M
Department of Pharmaceutics, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Minia University, Minia 61511, Egypt.
Pharmaceutics. 2021 Apr 19;13(4):581. doi: 10.3390/pharmaceutics13040581.
Nicergoline (NIC) is a semisynthetic ergot alkaloid derivative applied for treatment of dementia and other cerebrovascular disorders. The efficacy of sesame oil to slow and reverse the symptoms of neurodegenerative cognitive disorders has been proven. This work aimed to formulate and optimize sesame oil-based NIC-nanostructured lipid carriers (NIC-NLCs) for intranasal (IN) delivery with expected synergistic and augmented neuroprotective properties. The NIC-NLC were prepared using sesame oil as a liquid lipid. A three-level, three-factor Box-Behnken design was applied to statistically optimize the effect of sesame oil (%) of the total lipid, surfactant concentration, and sonication time on particle size, zeta potential, and entrapment efficacy as responses. Solid-state characterization, release profile, and ex vivo nasal permeation in comparison to NIC solution (NIC-SOL) was studied. In vivo bioavailability from optimized NIC-NLC and NIC-SOL following IN and IV administration was evaluated and compared. The optimized NIC-NLC formula showed an average particle size of 111.18 nm, zeta potential of -15.4 mV, 95.11% entrapment efficacy (%), and 4.6% loading capacity. The NIC-NLC formula showed a biphasic, extended-release profile (72% after 48 h). Permeation of the NIC-NLC formula showed a 2.3 enhancement ratio. Bioavailability studies showed a 1.67 and 4.57 fold increase in plasma and brain following IN administration. The results also indicated efficient direct nose-to-brain targeting properties with the brain-targeting efficiency (BTE%) and direct transport percentage (DTP%) of 187.3% and 56.6%, respectively, after IN administration. Thus, sesame oil-based NIC-NLC can be considered as a promising IN delivery system for direct and efficient brain targeting with improved bioavailability and expected augmented neuroprotective action for the treatment of dementia.
尼麦角林(NIC)是一种半合成麦角生物碱衍生物,用于治疗痴呆症和其他脑血管疾病。芝麻油减缓并逆转神经退行性认知障碍症状的功效已得到证实。本研究旨在制备并优化基于芝麻油的尼麦角林纳米结构脂质载体(NIC-NLCs),用于鼻腔给药,以期获得协同增强的神经保护特性。以芝麻油作为液态脂质制备NIC-NLC。采用三水平、三因素的Box-Behnken设计,以总脂质中芝麻油的百分比、表面活性剂浓度和超声处理时间为因素,以粒径、zeta电位和包封率为响应变量,进行统计学优化。研究了NIC-NLC的固态表征、释放曲线,并与尼麦角林溶液(NIC-SOL)进行了体外鼻腔渗透比较。评估并比较了优化后的NIC-NLC和NIC-SOL经鼻腔和静脉给药后的体内生物利用度。优化后的NIC-NLC配方平均粒径为111.18 nm,zeta电位为-15.4 mV,包封率为95.11%,载药量为4.6%。NIC-NLC配方呈现双相缓释曲线(48小时后释放72%)。NIC-NLC配方的渗透增强比为2.3。生物利用度研究表明,鼻腔给药后血浆和脑组织中的药物浓度分别提高了1.67倍和4.57倍。结果还表明,该制剂具有高效的直接鼻脑靶向特性,鼻腔给药后脑靶向效率(BTE%)和直接转运百分比(DTP%)分别为187.3%和56.6%。因此,基于芝麻油的NIC-NLC可被视为一种有前景的鼻腔给药系统,可实现直接、高效的脑靶向,提高生物利用度,并有望增强神经保护作用,用于治疗痴呆症。